Cargando…
Recent trends in specialty pharma business model
The recent rise of specialty pharma is attributed to its flexible, versatile, and open business model while the traditional big pharma is facing a challenging time with patent cliff, generic threat, and low research and development (R&D) productivity. These multinational pharmaceutical companies...
Autor principal: | Ku, Mannching Sherry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Food and Drug Administration
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345453/ https://www.ncbi.nlm.nih.gov/pubmed/28911475 http://dx.doi.org/10.1016/j.jfda.2015.04.008 |
Ejemplares similares
-
Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
por: Fulford-Smith, Antony, et al.
Publicado: (2022) -
Ideation and implementation of an open science drug discovery business model – M4K Pharma
por: Morgan, Maxwell Robert, et al.
Publicado: (2018) -
Digital health: trends, opportunities and challenges in medical devices, pharma and bio-technology
por: Kasoju, Naresh, et al.
Publicado: (2023) -
Big Pharma (The Play)
por: Bero, Lisa
Publicado: (2007) -
The Image of Pharma
Publicado: (2007)